Chai Discovery Partners with Bristol Myers Squibb to Advance AI-Powered Antibody Discovery

{
  "signal_id": "4a310577-60f1-92c4-4f06-3985818e16b5",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-08-21T08:46:25+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://hlth.com/insights/news/chai-discovery-partners-with-bristol-myers-squibb-to-advance-ai-powered-antibody-discovery",
    "title": "Chai Discovery Partners with Bristol Myers Squibb to Advance AI-Powered Antibody Discovery - HLTH",
    "excerpt": "Chai Discovery has announced a strategic collaboration with Bristol Myers Squibb (BMS) to use artificial intelligence to accelerate the discovery and engineering of therapeutic antibodies. Under the agreement, BMS will integrate Chai's proprietary molecular folding and de novo design models across its drug discovery portfolio, expanding the use of generative AI to identify and design new biological medicines. Chai's platform functions as a computer-aided design system for biology, using AI models to predict molecular structures, understand biochemical interactions and design biomolecules with specific properties. Rather than relying primarily on traditional experimental screening of large libraries of potential antibodies, the technology can generate antibody sequences and structures from scratch based on predefined biological and biophysical requirements. The approach could help researchers move from target identification to promising candidates more quickly. The collaboration is particularly relevant for complex or historically difficult drug targets, including flexible proteins, multi-pass membrane proteins and disease-related epitopes that can be challenging to address using conventional antibody discovery techniques. By modeling interactions at the molecular level, Chai aims to help researchers explore a broader range of potential therapeutic candidates while reducing the...",
    "product": "molecular folding and de novo design models",
    "summary": "Bristol Myers Squibb will integrate Chai Discovery's proprietary molecular folding and de novo design models across its drug discovery portfolio.",
    "planning": true,
    "image_url": "https://d21uyekz5eda4b.cloudfront.net/portal-assets/images/content/thumbnail/06e48508-5858-48cb-b118-075fcd54aee1_9141abd8-a490-4f8b-b441-4a475f64b6fa",
    "confidence": 0.9,
    "product_data": {
      "name": "molecular folding and de novo design models",
      "full_text": "Chai's proprietary molecular folding and de novo design models",
      "fuzzy_match": false,
      "release_type": "model"
    },
    "product_tags": [
      "future_tech",
      "general_technology",
      "data"
    ],
    "published_at": "2026-08-21T08:46:25Z",
    "article_sentence": "Under the agreement, BMS will integrate Chai's proprietary molecular folding and de novo design models across its drug discovery portfolio, expanding the use of generative AI to identify and design new biological medicines.",
    "related_company_name": "Chai Discovery",
    "related_company_domain": "chaidiscovery.com"
  }
}

curl https://signals.autobound.ai/v1/signals/4a310577-60f1-92c4-4f06-3985818e16b5 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","limit":20}'